Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients

Jl, Teruel; Lasunción, Miguel A.; Rivera, Maite; Aguilera, Abelardo; Ortega, Henar; Tato, A; Marcén, R.; Ortuño, J

doi:10.1016/s0272-6386(97)90340-1

Cited by 41 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies concluded that androgen therapy is associated with high incidence of adverse effect in lipid profiles [4,5,34] while others have shown that ND has no marked effect on the lipid profile [2]. In this study evaluating the effect of the drug on lipid profiles showed significantly increase in C and marked decrease in HDL-C levels, without significant changes in TG level.…”

Section: Discussionmentioning

confidence: 55%

“…The cause of discrepancy is probably multifactorial, but malnutrition, anemia, hypoalbuminemia, reduced muscle mass and increased atherosclerosis are common in dialysis patients [1-3]. Therapies designed to improve the nutritional status, control of anemia and atherosclerosis of hemodialysis patients might therefore be expected to improve outcome [2,4]. Anabolic agents, such as human growth hormone (HuGH) can improve nitrogen balance, reduces urea generation and protein catabolic rate in long term hemodialysis patients.…”

Section: Introductionmentioning

confidence: 99%

“…In spite that the drug is associated with high incidence of adverse effects including acne, virilization, abnormal liver function, discomfort from intramuscular injection [7], It can increase weight, triceps skinfold thickness, nitrogen balance and bone mineral density [2,7]. Moreover a reduction in the level of atherogenic lipoprotein (a) [Lp(a)] particles following ND administration to hemodialysis patients has been described [4]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

et al. 2004

View full text Add to dashboard Cite

Malnutrition, anemia and increased atherosclerosis are the main causes of mortality in hemodialysis patients. Therapies designed to improve the disorders might therefore be expected to improve outcome. The effects of Nandrolone Decanoate (ND), in 64 stable hemodialysis patients, were studied with respect to the following parameters: nutritional status, hematological indexes, lipid profiles including serum levels of lipoprotein(a) [Lp(a)] in terms of differences in apolipoprotein(a) [apo(a)]. The patients were treated with ND at dose of 100 mg/I.M./week for 4 months. After 2 and 4 months of treatment the elevations in the serum levels of albumin (p < 0.0001), creatinine (p < 0.009), hemoglobin (p < 0.03), hematocrit (p < 0.03), cholesterol (p = 0.007) and triglyceride (p < 0.04) were noticed. Marked decrease in the concentration of high-density lipoprotein cholesterol (p = 0.007) and Lp(a) (p < 0.0001) were also found. These effects after 2 months of treatment withdrawal were relatively constant. By dividing patients according to the baseline Lp(a) levels and molecular weight of apo(a) isoform, it was noticed that the decrease in serum Lp(a) was significant in patients with high Lp(a) (>30 mg/dl) than those of with low Lp(a) (<30 mg/dl), irrespective of apo(a) molecular weight. It may be suggested that, ND has beneficial effect on nutritional status and treatment of anemia in hemodialysis patients. In spite the adverse effect of ND on lipid profile, it decreases Lp(a) mostly in patients with high serum Lp(a) preferently by the effect on apo(a) gene transcriptional activity.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

et al. 2004

View full text Add to dashboard Cite

show abstract

“…At the completion of the study, subjects taking AAS had lower high density lipoprotein (HDL) cholesterol and elevated low density lipoprotein concentrations. Similarly, weekly im administration of nandrolone decanoate (200 mg/wk) to 14 hemodialysis patients resulted in a significant decrease in HDL-2 cholesterol and apolipoprotein A-I levels (89). An increase in the concentrations of apolipoprotein B and triglycerides was also seen.…”

Section: Muscular-skeletal Injurymentioning

confidence: 91%

Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases

Basaria

Wahlstrom

Dobs

2001

The Journal of Clinical Endocrinology &Amp; Metabolism

228

175

View full text Add to dashboard Cite

The purpose of this study was to review the preclinical and clinical literature relevant to the efficacy and safety of anabolic androgen steroid therapy for palliative treatment of severe weight loss associated with chronic diseases. Data sources were published literature identified from the Medline database from January 1966 to December 2000, bibliographic references, and textbooks. Reports from preclinical and clinical trials were selected. Study designs and results were extracted from trial reports. Statistical evaluation or meta-analysis of combined results was not attempted.Androgenic anabolic steroids (AAS) are widely prescribed for the treatment of male hypogonadism; however, they may play a significant role in the treatment of other conditions as well, such as cachexia associated with human immunodeficiency virus, cancer, burns, renal and hepatic failure, and anemia associated with leukemia or kidney failure. A review of the anabolic effects of androgens and their efficacy in the treatment of these conditions is provided. In addition, the numerous and sometimes serious side effects that have been known to occur with androgen use are reviewed.Although the threat of various side effects is present, AAS therapy appears to have a favorable anabolic effect on patients with chronic diseases and muscle catabolism. We recommend that AAS can be used for the treatment of patients with acquired immunodeficiency syndrome wasting and in severely catabolic patients with severe burns. Preliminary data in renal failure-associated wasting are also positive. Advantages and disadvantages should be weighed carefully when comparing AAS therapy to other weight-gaining measures. Although a conservative approach to the use of AAS in patients with chronic diseases is still recommended, the utility of AAS therapy in the attenuation of severe weight loss associated with disease states such as cancer, postoperative recovery, and wasting due to pulmonary and hepatic disease should be more thoroughly investigated. (J Clin Endocrinol Metab 86: 5108 -5117, 2001)

show abstract

“…30 Several studies have found lowered serum Lp(a) concentrations after treatment with testosterone enanthate in eugonadal men, 26 and with nandrolone decanoate in postmenopausal women 24 25 and haemodialysis patients. 31 In a cross sectional study, Cohen and co-workers 23 reported that the proportion of subjects with high serum Lp(a) concentrations was lower in multidrug AAS using strength athletes than in their non-using counterparts, suggesting a suppressive effect of multidrug use of AASs on serum Lp(a) concentrations. In our study, polydrug regimens of AAS use were found to have a strong lowering effect on Lp(a), and the administration of only nandrolone decanoate induced a strong, although non-significant, reduction in this variable.…”

Section: Lowering Lp(a) Concentrationsmentioning

confidence: 99%

Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a)

Hartgens¹

2004

Br J Sports Med

168

117

View full text Add to dashboard Cite

Objectives:To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes.Methods:In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined.Results:In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l. Serum Lp(a) declined from 189 (315) to 32 (63) U/l. Total cholesterol and triglycerides did not change significantly. Alterations after eight and 14 weeks of AAS administration were comparable. No changes occurred in the controls. Six weeks after AAS cessation, serum HDL-C, HDL2-C, Apo-A1, Apo-B, and Lp(a) had still not returned to baseline concentrations. Administration of AAS for 14 weeks was associated with slower recovery to pretreatment concentrations than administration for eight weeks. In study 2, nandrolone decanoate did not influence serum triglycerides, total cholesterol, HDL-C, HDL2-C, HDL3-C, Apo-A1, and Apo-B concentrations after four and eight weeks of intervention, nor six weeks after withdrawal. However, Lp(a) concentrations decreased significantly from 103 (68) to 65 (44) U/l in the nandrolone decanoate group, and in the placebo group a smaller reduction from 245 (245) to 201 (194) U/l was observed. Six weeks after the intervention period, Lp(a) concentrations had returned to baseline values in both groups.Conclusions:Self administration of several AASs simultaneously for eight or 14 weeks produces comparable profound unfavourable effects on lipids and lipoproteins, leading to an increased atherogenic lipid profile, despite a beneficial effect on Lp(a) concentration. The changes persist after AAS withdrawal, and normalisation depends on the duration of the drug abuse. Eight weeks of administration of nandrolone decanoate does not affect lipid and lipoprotein concentrations, although it may selectively reduce Lp(a) concentrations. The effect of this on atherogenesis remains to be established.

show abstract

Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients

Cited by 41 publications

References 33 publications

Untitled

Untitled

Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases

Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a)

Contact Info

Product

Resources

About